drugset / Trial / NCT00189553
Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse
Phase 3
Completed
976 enrolled
ARCAGY/ GINECO GROUP
AGO Study Group · collabArbeitsgemeinschaft Gynaekologische Onkologie Austria · collabAustralia New Zealand Gynaecological Oncology Group · collabEuropean Organisation for Research and Treatment of Cancer - EORTC · collabNCIC Clinical Trials Group · collabNSGO · collabSchering-Plough · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a study of the efficacy and safety of Caelyx (pegylated liposomal doxorubicin) in combination with carboplatin compared to the standard treatment of paclitaxel and carboplatin in patients with epithelial ovarian cancer in late relapse (\> 6 months).
Timeline
- Start
- 2005-04
- Primary completion
- 2009-01
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Comparator | Paclitaxel | Small molecule | 175 mg/m2 | — |
| Subject | Pegylated liposomal doxorubicin | Unknown | 30 mg/m2 | — |